Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib + rituximab + dexamethasone in relapsed or progressive Waldenström macroglobulinemia
NL-OMON27880Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Oct 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ixazomib, rituximab and dexamethasone in Waldenström macroglobulinemia (WM) (2 arms), sponsored by HOVON. Primary endpoints: Recommended phase II dose and Overall response rate. Started Oct 2014; status: active, not recruiting.
02
Drugs
ixazomibrituximabdexamethasone
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NL-OMON27880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27880.